UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16
OR 15d-16 OF THE
SECURITIES EXCHANGE ACT
OF 1934
For the month of July 2023
Commission File Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its
Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
On July 14, 2023, CureVac N.V. (the “Company”) issued
a press release announcing that Chief Scientific Officer Dr. Igor Splawski will step down effective July 14, 2023. During the search
for a successor, CureVac’s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac’s unique
mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics
The information
included in this Form 6-K (including Exhibit 99.1, but excluding the statements of the Company’s Chief Scientific Officer and
the Chairman of the Supervisory Board contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s
Registration Statement on Form F-3 (File No. 333-259613).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CUREVAC N.V. |
|
|
|
|
By: |
/s/ Alexander Zehnder |
|
|
|
Chief Executive Officer |
Date: July 14, 2023
EXHIBIT INDEX
Exhibit 99.1
CureVac Announces Update to the Management Team
TÜBINGEN, Germany / BOSTON, USA –
July 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class
of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Dr. Igor Splawski, CureVac’s
Chief Scientific Officer, will step down effective July 14, 2023 to return to early-stage research in the United States. During the search
for a successor, CureVac’s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac’s unique mRNA
technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.
“We are extremely grateful for Igor’s
many contributions to CureVac’s research strategy and his vital role in bringing the company’s differentiated mRNA technology
to the next level,” said Jean Stéphenne, Chairman of the Supervisory Board of CureVac. “I would like to sincerely thank
him for his leadership and wish him all the best for his next steps.”
“Leading the development of CureVac’s
mRNA technology and preclinical pipeline in these decisive years of strong growth and technology evolution has been a great privilege,”
said Dr. Igor Splawski. “I truly enjoyed working with our brilliant scientists, who have pioneered some of the most significant
breakthroughs in mRNA technology and continue to advance this exciting field. I would like to thank my CureVac colleagues for their trust
and support.”
About CureVac
CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July
2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based
on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium,
Switzerland and the U.S. Further information can be found at www.curevac.com.
CureVac
Media and Investor Relations Contact
Dr. Sarah
Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen,
Germany
T: +49 7071
9883-1298
M: +49 160
90 496949
sarah.fakih@curevac.com
Forward-Looking Statements CureVac
This press release contains statements that constitute
“forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.
and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services
GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the “company”) regarding future events or
future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the
company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market
growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,”
“believe,” “estimate,” “plan,” “seek,” “project,” or “expect,”
“may,” “will,” “would,” “could,” “potential,” “intend,” or “should,”
the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s
performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties
and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide
financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing,
expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products,
ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures
from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s
business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.
Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it
thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does
not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions
to any such statements to reflect future events or developments, except as required by law. For further information, please reference
the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by
visiting EDGAR on the SEC website at www.sec.gov.
CureVac NV (NASDAQ:CVAC)
過去 株価チャート
から 5 2024 まで 6 2024
CureVac NV (NASDAQ:CVAC)
過去 株価チャート
から 6 2023 まで 6 2024